43 employees
Reinventing drug development from the ground up to make safe, effective oligonucleotide-based medicines possible on demand.
2019
$40M
from 3 investors over 3 rounds
Creyon Bio raised $40M on March 8, 2022
Investors: Casdin Capital, LLC, Lux Capital and DCVC Bio